Log In
BCIQ
Print this Print this
 

NUC-202

  Manage Alerts
Collapse Summary General Information
Company Ligand Pharmaceuticals Inc.
DescriptionTargeted anti-cancer analog
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationLiver cancer
Indication DetailsTreat hepatocellular carcinoma
Regulatory Designation
PartnerNucorion Pharmaceuticals Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/29/2016

Undisclosed

0

Undisclosed

Get a free BioCentury trial today